Quirós PF, Cornejo GJA

Language: Spanish
References: 15
Page:
PDF size: 120.72 Kb.

ABSTRACT

Hepatocellular adenoma (HCA) is a benign hepatocellular neoplasm that develops in a normal appearing liver. It commonly occurs in women and can appear sporadically in men. It is related to the use of medications that contain estrogen, such as oral contraceptives, and other risk factors. In general, its clinical presentation is asymptomatic and is usually incidentally found on imaging tests. The classification is based on genotypic and phenotypic characteristics. Management is decided according to the presence of symptoms, the patient sex, size and progression. Complications might include, intraperitoneal hemorrhage due to rupture of the hepatic adenoma, requiring the need of surgical intervention.

REFERENCES

1. Townsend. Sabiston textbook of surgery: The biological basis of modern surgical practice. 21st ed. Townsend CM Jr, editor. Filadelfia, PA, United States of America: Elsevier - Health Sciences Division; 2021.

2. Cameron JL, Cameron AM, editores. Terapias Quirúrgicas Actuales. 13a ed. Elsevier; 2020.

3. Curry MP, Afdhal NH. Hepatocellular adenoma. Wolters Kluwer Health. 2021 [cited Jan 03, 2022].

4. Van Rosmalen BV, Furumaya A, Klompenhouwer AJ, Tushuizen ME, Braat AE, Reinten RJ, et al. Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course. Liver Int [Internet]. 2021;41(10):2474–84. Doi: https://doi.org/10.1111/liv.14989

5. Haring MPD, Gouw ASH, de Haas RJ, Cuperus FJC, de Jong KP, de Meijer VE. The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study. Liver Int [Internet]. 2019;39(5):905–13. Doi: https://doi.org/10.1053/j.gastro.2016.11.042

6. Rajendiran G. Not All Hepatocellular Adenomas are Caused by the Hormonal Oral Contraceptive. South Dakota Medicine. Jul, 2021;74(7):302-303. Available from: https://pubmed.ncbi.nlm.nih.gov/34449989/

7. Bioulac-Sage P, Gouw ASH, Balabaud C, Sempoux C. Hepatocellular adenoma: what we know, what we do not know, and why it matters. Histopathology [Internet]. 2022;80(6):878–97. Doi: https://doi.org/10.1111/his.14605

8. Haring MPD, Cuperus FJC, Duiker EW, de Haas RJ, de Meijer VE. Scoping review of clinical practice guidelines on the management of benign liver tumours. BMJ Open Gastroenterol [Internet]. 2021;8(1):e000592. Doi: https://doi.org/10.1136/bmjgast-2020-000592

9. Wang X, Zhang X. Hepatocellular adenoma: Where are we now? World J Gastroenterol [Internet]. 2022;28(14):1384–93 Doi: https://doi.org/10.3748/wjg.v28.i14.1384

10. Klompenhouwer AJ, de Man RA, Dioguardi Burgio M, Vilgrain V, Zucman-Rossi J, Ijzermans JNM. New insights in the management of Hepatocellular Adenoma. Liver Int [Internet]. 2020;40(7):1529–37 Doi: https://doi.org/10.1111/liv.14547

11. Feldman M, Friedman LS, Brandt LJ, editores. Sleisenger Y Fordtran. Enfermedades Digestivas y Hepáticas: Fisiopatología, Diagnóstico y Tratamiento. 11a ed. Elsevier; 2021.

12. Yeo CJ. Shackelford’s surgery of the alimentary tract, 2 volume set. 8a ed. Filadelfia, PA, United States of America: Elsevier - Health Sciences Division; 2018.

13. Nault JC, Blanc JF, Moga L, Calderaro J, Dao T, Guiu B, et al. Non-invasive diagnosis and follow-up of benign liver tumours. Clin Res Hepatol Gastroenterol [Internet]. 2022;46(1):101765. Doi: https://doi.org/10.1016/j.clinre.2021.101765

14. Mauro E, Forner A. Hepatocellular adenoma in men: Is it time for a precision approach? Liver Int [Internet]. 2021;41(10):2246–8. Doi: https://doi.org/10.1111/liv.15050

15. Beaufrère A, Paradis V. Hepatocellular adenomas: review of pathological and molecular features. Hum Pathol [Internet]. 2021;112:128–37. Doi: https://doi.org/10.1016/j.humpath.2020.11.016.